RxDoctor Payments Data

Chandra Koneru, MD

Internal Medicine · Athens, ALNPI 1982758132

Payments from drug & device makers

$205in general payments, 2019–2025

Across 11 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$58
  • Novo Nordisk$56
  • Novartis$26
  • AstraZeneca$23
  • Merck$17
  • E.r. Squibb & Sons, L.L.C.$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$205100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$205 in reported general payments places this provider in the 35th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$190,927
Medicare patients
475
Services billed
3,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin152$138,317
EliquisApixaban120$132,236
JanuviaSitagliptin Phosphate142$132,203
OzempicSemaglutide74$113,971
MounjaroTirzepatide82$100,401
FarxigaDapagliflozin Propanediol57$56,417
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$37,012
XareltoRivaroxaban32$34,596
InvokanaCanagliflozin26$25,313
EntrestoSacubitril/Valsartan31$21,407
JanumetSitagliptin Phos/Metformin Hcl15$11,045
Breo ElliptaFluticasone/Vilanterol13$9,749
TradjentaLinagliptin13$8,588
MyrbetriqMirabegron11$6,482
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$17$143,248157 claims
Novo NordiskOzempic$56$113,97174 claims
AstraZenecaFarxiga$23$56,41757 claims
NovartisEntresto$26$21,40731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →